Aggressive GI cancers grow by exploiting signals from surrounding stromal cells and, as only recently discovered, by forming functional interactions with neuronal cells. This PhD project will dissect these communication networks in patient-derived models of esophageal, pancreatic and colorectal cancer. Using single-cell and spatial transcriptomics and proteomics, you will map ligand–receptor and signaling circuits in tumor and stromal populations. By using in vitro co‑culture systems (organoids, CAFs, immune cells, iPSC-derived neurons) with targeted perturbations you will test how specific pathways control stemness, growth and therapy resistance. In collaboration with neuroscientists, key neuron–tumor interactions will be validated in vivo, revealing molecular targets for future interventions.
You will perform this work in a highly collaborative environment that links oncology and neuroscience within the NWO‑funded ADORE KIC‑LTP consortium. The position is for four years (with an initial 12‑month contract), leading to a PhD from the University of Amsterdam.
Would you like to know more about the different phases within the PhD trajectory? You can read more about this here.
The main purpose of this PhD project is to uncover how tumor, stromal and neuronal cells communicate to drive aggressive growth and therapy resistance in gastrointestinal cancers, and to identify molecular circuits that can be targeted therapeutically. To achieve this, you will combine advanced experimental models with state‑of‑the‑art single‑cell and spatial technologies.
Activities include:
You will report on your findings in regular work meetings, conferences, and scientific publications in reputable journals. You will supervise undergraduate students.
Applicants bring the following:
We are looking for the following personality traits:
Watch this video with more information about joining Amsterdam UMC Research BV.
The position is embedded in the Laboratory for Experimental Oncology and Radiobiology in the new RDC ADORE building on the VUmc campus. Here, you will join a large, interdisciplinary team of young researchers working on gastrointestinal malignancies such as esophageal, pancreatic and colorectal cancer. Amsterdam UMC is the main referral center for many of these cancers in the Netherlands, and our research is internationally leading. The position is NWO‑funded.
The project is part of the ADORE initiative, which aims to bring together cancer and neuroscience expertise and drive biomedical breakthroughs in both fields. This project is a clear example of that ambition, and you will work closely with researchers from the Center for Neurogenomics & Cognitive Research at Vrije Universiteit Amsterdam.
In addition, there is an active effort to establish single‑cell proteomics capabilities within ADORE, and this project is tightly connected to that development. You will work together with the proteomics unit and be at the forefront of research technology. You will enroll in the Amsterdam UMC Doctoral School and work towards a PhD from the University of Amsterdam.
Amsterdam UMC Research BV
Amsterdam UMC Research BV supports non-profit scientific research. In doing so, we provide researchers with everything they need to excel. Our principal investigators (PIs) and project leaders offer support in the field of project management, finance and human resources. In medical scientific research projects, legal support is also provided.
Watch the video to find out more.
The first round of interviews is scheduled in May/June. We ask you to take this into account in advance.
f you have any questions about this position, please feel free to contact Maarten Bijlsma at (+31)20 444 8099 or m.f.bijlsma@amsterdamumc.nl.
For more information about the application procedure, please contact Chey Edwards, recruitment advisor, at c.i.edwards@amsterdamumc.nl.
A reference check, screening and hiring assessment may be part of the procedure. Read here whether that applies to you. If you join us, we ask you for a VOG (Certificate of Good Conduct).
Internal candidates will be given priority over external candidates in case of equal suitability.
Acquisition in response to this vacancy will not be considered.


